HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), b… Read more
Market Cap & Net Worth: HUTCHMED (China) Limited (HMDCF)
HUTCHMED (China) Limited (PINK:HMDCF) has a market capitalization of $2.75 Billion ($2.75 Billion) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #5547 globally and #3261 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying HUTCHMED (China) Limited's stock price $3.21 by its total outstanding shares 859517342 (859.52 Million).
HUTCHMED (China) Limited Market Cap History: 2017 to 2025
HUTCHMED (China) Limited's market capitalization history from 2017 to 2025. Data shows change from $5.89 Billion to $2.75 Billion (-5.15% CAGR).
HUTCHMED (China) Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how HUTCHMED (China) Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
5.01x
HUTCHMED (China) Limited's market cap is 5.01 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
6.02x
HUTCHMED (China) Limited's market cap is 6.02 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $5.89 Billion | $241.20 Million | -$26.74 Million | 24.44x | N/A |
| 2018 | $5.25 Billion | $214.11 Million | -$74.81 Million | 24.53x | N/A |
| 2019 | $5.29 Billion | $204.89 Million | -$106.02 Million | 25.84x | N/A |
| 2020 | $4.39 Billion | $227.98 Million | -$125.73 Million | 19.26x | N/A |
| 2021 | $4.39 Billion | $356.13 Million | -$194.65 Million | 12.33x | N/A |
| 2022 | $2.58 Billion | $426.41 Million | -$360.83 Million | 6.05x | N/A |
| 2023 | $3.28 Billion | $838.00 Million | $100.78 Million | 3.91x | 32.54x |
| 2024 | $3.28 Billion | $630.20 Million | $37.73 Million | 5.20x | 86.91x |
| 2025 | $2.75 Billion | $549.32 Million | $457.58 Million | 5.01x | 6.02x |
Competitor Companies of HMDCF by Market Capitalization
Companies near HUTCHMED (China) Limited in the global market cap rankings as of March 19, 2026.
Key companies related to HUTCHMED (China) Limited by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
HUTCHMED (China) Limited Historical Marketcap From 2017 to 2025
Between 2017 and today, HUTCHMED (China) Limited's market cap moved from $5.89 Billion to $ 2.75 Billion, with a yearly change of -5.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.75 Billion | -15.99% |
| 2024 | $3.28 Billion | 0.00% |
| 2023 | $3.28 Billion | +27.17% |
| 2022 | $2.58 Billion | -41.29% |
| 2021 | $4.39 Billion | 0.00% |
| 2020 | $4.39 Billion | -17.05% |
| 2019 | $5.29 Billion | +0.82% |
| 2018 | $5.25 Billion | -10.91% |
| 2017 | $5.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of HUTCHMED (China) Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.75 Billion USD |
| MoneyControl | $2.75 Billion USD |
| MarketWatch | $2.75 Billion USD |
| marketcap.company | $2.75 Billion USD |
| Reuters | $2.75 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.